ADVANCES IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES (IBD) IN CHILDREN: BIOLOGICAL THERAPIES, MICROBIOTA INTERVENTIONS, AND PERSONALIZATION OF TREATMENT

Abstract

Inflammatory bowel diseases (IBDs), such as Crohn's Disease (CD) and Ulcerative Colitis (UC), are chronic and complex conditions that mainly affect the pediatric population, compromising the growth, development, and quality of life of children. These diseases have proven challenging in the pediatric context due to their variable clinical presentation and the need for effective therapeutic strategies that can minimize the long-term effects. This review article aims to analyze the new perspectives in the management of IBDs in children, with an emphasis on biological therapies, interventions in the intestinal microbiota, genetic research, and the importance of personalization of treatment. Recent studies, including those conducted by Brazilian researchers, indicate that biological therapies have shown efficacy in inducing and maintaining disease remission, while interventions in the gut microbiota, such as the use of probiotics and fecal microbiota transplantation, emerge as promising options for modulating the inflammatory response. In addition, genetic research is providing valuable insights into the predisposing factors for IBD, which could lead to more targeted and personalized treatments. Personalization of treatment, taking into account the individual characteristics of each patient, is crucial to optimize results and minimize the adverse effects of therapies. In summary, advances in the management of pediatric IBDs are increasingly focused on combining new therapeutic approaches and personalizing treatment.